TRAIL selectively induces apoptotic cell death in a variety of cancer cells and is regarded as a therapeutic apoptosis inducing treatment in some clinic trials, but TRAIL resistance is prevalent in many solid cancers including prostate cancer. Here, TNFSF10 is linked to Familial prostate cancer.